Trial Outcomes & Findings for Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial (NCT NCT01829243)

NCT ID: NCT01829243

Last Updated: 2023-10-26

Results Overview

Visual Analogue Scale for Pain operationally is a 100 mm line anchored by word descriptors at each end. The patient marks a point on the line that reflects their current pain state. The distance in mm from the left anchor point is the score. Higher scores indicate more pain.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

26 participants

Primary outcome timeframe

Baseline, Week 1, 2,4, and 6 weeks

Results posted on

2023-10-26

Participant Flow

Patients were randomized to receiving milnacipran-washout-placebo or placebo- washout-milnacipran for 6 weeks, followed by a 1 week washout and then cross over to the other arm for another 6 weeks. The overall trial lasted 13 weeks starting on July 2011 and ending in May 2013.

Participant milestones

Participant milestones
Measure
Milnacipran First, Then Placebo
Patients randomized to receiving milnacipran first.
Placebo First, Then Milnacipran
Patients randomized to receive placebo first
First Intervention
STARTED
11
15
First Intervention
COMPLETED
7
13
First Intervention
NOT COMPLETED
4
2
Washout Period of 1 Week
STARTED
7
13
Washout Period of 1 Week
COMPLETED
7
13
Washout Period of 1 Week
NOT COMPLETED
0
0
Second Intervention
STARTED
7
13
Second Intervention
COMPLETED
7
13
Second Intervention
NOT COMPLETED
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Milnacipran First, Then Placebo
Patients randomized to receiving milnacipran first.
Placebo First, Then Milnacipran
Patients randomized to receive placebo first
First Intervention
Screen Failure
4
2

Baseline Characteristics

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Subjects Who Completed the Study
n=20 Participants
Age, Continuous
47.6 years
STANDARD_DEVIATION 9.1 • n=99 Participants
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Sex: Female, Male
Female
18 Participants
n=99 Participants
Sex: Female, Male
Male
2 Participants
n=99 Participants
Region of Enrollment
United States
20 participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline, Week 1, 2,4, and 6 weeks

Population: Analysis employed Intent-to-Treat with Last Observation Carried Forward (LOCF) analysis. The Intent-to-Treat group (ITT) was comprised of all subjects who received at least one dose of the medication.

Visual Analogue Scale for Pain operationally is a 100 mm line anchored by word descriptors at each end. The patient marks a point on the line that reflects their current pain state. The distance in mm from the left anchor point is the score. Higher scores indicate more pain.

Outcome measures

Outcome measures
Measure
Milnacipran
n=20 Participants
Data is summarize for all patients while they were taking Milnacipran.
Placebo
n=20 Participants
Data is summarize for all patients while they were taking the placebo.
Visual Analogue Scale for Pain
Week 4
56.9 mm
Interval 2.7 to 57.1
54.4 mm
Interval 2.8 to 55.2
Visual Analogue Scale for Pain
Week 0
59.4 mm
Interval 4.5 to 59.5
68.6 mm
Interval 3.9 to 69.4
Visual Analogue Scale for Pain
Week 1
58.5 mm
Interval 3.4 to 59.1
66.2 mm
Interval 3.4 to 67.3
Visual Analogue Scale for Pain
Week 2
55.7 mm
Interval 3.0 to 56.3
61.5 mm
Interval 3.1 to 62.6
Visual Analogue Scale for Pain
week 6
54.4 mm
Interval 2.7 to 55.9
60.4 mm
Interval 2.5 to 60.5

PRIMARY outcome

Timeframe: Baseline, Week 1, 2,4, and 6 weeks

Population: Analysis employed Intent-to-Treat with Last Observation Carried Forward (LOCF) analysis. The Intent-to-Treat group (ITT) was comprised of all subjects who received at least one dose of the medication.

The Fatigue Severity Scale (FSS) is composed of nine items with a seven-point response format. The minimum score = 9 and maximum score possible = 63. Higher scores = greater fatigue severity. Sample questions include "I am easily fatigued" and "Exercise brings on my fatigue." In the initial validation study, internal consistency for the Fatigue Severity Scale was high for specific illness groups (MS and lupus) and healthy controls. The scale clearly distinguished patients from controls and it was moderately correlated with a single-item visual analogue scale of fatigue intensity. In all patients, clinical improvement in fatigue was associated with reductions in scores on the Fatigue Severity Scale. The Fatigue Severity Scale is also a practical measure due to its brevity and ease of administration and scoring.

Outcome measures

Outcome measures
Measure
Milnacipran
n=20 Participants
Data is summarize for all patients while they were taking Milnacipran.
Placebo
n=20 Participants
Data is summarize for all patients while they were taking the placebo.
Changes in The Fatigue Severity Scale (FSS)
Week 0
56.3 units on a scale
Interval 44.0 to 56.7
49.2 units on a scale
Interval 44.0 to 49.2
Changes in The Fatigue Severity Scale (FSS)
Week 1
54.0 units on a scale
Interval 44.0 to 54.5
53.4 units on a scale
Interval 44.0 to 53.6
Changes in The Fatigue Severity Scale (FSS)
Week 2
53.7 units on a scale
Interval 44.0 to 53.7
52.2 units on a scale
Interval 44.0 to 52.5
Changes in The Fatigue Severity Scale (FSS)
Week 4
54.1 units on a scale
Interval 44.0 to 54.5
52.8 units on a scale
Interval 44.0 to 53.1
Changes in The Fatigue Severity Scale (FSS)
Week 6
52.1 units on a scale
Interval 44.0 to 52.5
53.0 units on a scale
Interval 44.0 to 53.7

PRIMARY outcome

Timeframe: Baseline, Week 6

The composite BAC score is calculated by scoring each of the 6 individual tests (Verbal Memory Recall, Digit Sequencing, Token Motor Task, Verbal Fluency, Symbol Coding, and Tower of London), comparing each score to a healthy control sample to create z-scores, summing the z-scores, and rescaling the sum. The composite score range is -2127.8 to 1878.8, with higher scores indicating better cognition.

Outcome measures

Outcome measures
Measure
Milnacipran
n=20 Participants
Data is summarize for all patients while they were taking Milnacipran.
Placebo
n=20 Participants
Data is summarize for all patients while they were taking the placebo.
Composite Brief Assessment of Cognition (BAC) Score
Baseline
41.2 units on a scale
Standard Deviation 7.3
40.9 units on a scale
Standard Deviation 10.4
Composite Brief Assessment of Cognition (BAC) Score
Week 6
42.9 units on a scale
Standard Deviation 8.0
42.9 units on a scale
Standard Deviation 7.8

SECONDARY outcome

Timeframe: Baseline, Week 6

(MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition. The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning.

Outcome measures

Outcome measures
Measure
Milnacipran
n=20 Participants
Data is summarize for all patients while they were taking Milnacipran.
Placebo
n=20 Participants
Data is summarize for all patients while they were taking the placebo.
MATRICS Consensus Cognitive Battery Composite Score
Baseline
41.4 units on a scale
Standard Deviation 7.4
37.8 units on a scale
Standard Deviation 9.6
MATRICS Consensus Cognitive Battery Composite Score
Week 1
41.0 units on a scale
Standard Deviation 9.7
40.6 units on a scale
Standard Deviation 10.0

Adverse Events

Milnacipran

Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 18 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Milnacipran
n=20 participants at risk
Adverse events in this group occurred while subjects were taking Milnacipran.
Placebo
n=20 participants at risk
Adverse events in this group occurred while subjects were taking Placebo.
Psychiatric disorders
Depression
10.0%
2/20
10.0%
2/20
General disorders
Insomnia
10.0%
2/20
30.0%
6/20
General disorders
Tiredness
0.00%
0/20
5.0%
1/20
General disorders
Pain
5.0%
1/20
20.0%
4/20
Nervous system disorders
Dizziness
5.0%
1/20
10.0%
2/20
Nervous system disorders
Restlessness
0.00%
0/20
5.0%
1/20
Gastrointestinal disorders
Dry Mouth
0.00%
0/20
10.0%
2/20
Gastrointestinal disorders
Nausea
15.0%
3/20
5.0%
1/20
Gastrointestinal disorders
Diarrhea
0.00%
0/20
5.0%
1/20
Metabolism and nutrition disorders
Appetite change
5.0%
1/20
5.0%
1/20
Renal and urinary disorders
Urinary difficulty
5.0%
1/20
0.00%
0/20
Skin and subcutaneous tissue disorders
Itching
5.0%
1/20
0.00%
0/20

Additional Information

Ashwin A. Patkar, MD

Duke University Medical Center

Phone: 919-668-3626

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place